Title: Evidence for toxic COVID-19 vaccine lots identified in the Vaccine Adverse Event Reporting System (VAERS, USA). Carlton B. Brown, 2022.
Evidentiary Document: This VAERS study supported an evidentiary document, and Open Letter sent to New Zealand’s Prime Minister, Minister of Health, other Ministers, and many senior healthcare-related executives, specialists, and researchers. This evidentiary document provided the results of my private research into (1) negative COVID-19 vaccine effectiveness and vaccine failure in New Zealand, England, Scotland, and Canada across the Omicron wave and Globally (2021), (2) the evidence for toxic vaccine lots in the US Vaccine Adverse Event Reporting System database and its global implications, and (3) the significant evidence for SARS-CoV-2’s gain-of-function origin and the mechanisms used to enhance infectivity and pathogenicity (https://grandsolarminimum.com/2022/12/01/covid-19-vaccine-harm-evidence/).
Download a PDF copy of this US Vaccine Adverse Event Reporting System (VAERS) study that investigated the evidence for toxic COVID-19 vaccine lots (Toxic COVID-19 vaccine Lots (VEARS, USA)) and the associated .zip file containing the VAERS data text files (VAERS_COVID-19-Vaccine_Death-Hospitalization_data_07122021_Archive).
Abstract:
According to this analysis of the US Government’s Vaccine Adverse Event Reporting System data (VAERS), one year of COVID-19 vaccine-associated deaths and hospitalizations (“adverse outcomes” by 07/12/2021) were equivalent in number to all other vaccine adverse outcomes in the USA over the last 32 and 20 years respectively. A small minority of vaccine lots was associated with the majority of these COVID-19 vaccine-related adverse outcomes. Furthermore, there was an uneven distribution of negative outcomes across vaccine lots (i.e., skewed and peaked). Most of these adverse outcomes were associated with a minority of lots sent to a larger number of states. This minority of lots had a significantly higher weighted mean and median of adverse outcomes per state per lot fraction sent to a State when lots were shipped to ≥11 states (deaths) and ≥19 States (hospitalizations) compared with those sent to state totals below these thresholds. These issues were replicated with all US COVID-19 vaccines. These results would imply the presence of significant differences in vaccine lot composition or specification, or there was targeted vaccine use in high-risk demographics (i.e., the elderly) coordinated via a central vaccine distribution mechanism. Ninety percent of all vaccine-related adverse outcomes were associated with mRNA gene-therapy-vaccines.
Recent Comments